BASEL, Switzerland,
Oct 4 /PRNewswire-FirstCall/ -
Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES)
introduces a Neuro-biomarker which is linked to a series of
Neuro-Bio tests. This will permit to understand the science behind
them and how they each will contribute to a progressive clinical
investigation involving the input and output of the brain.
All Neuro-biomarkers are expressed with a numeric value to ensure
that doctors can rapidly see and comprehend how the results will
confirm their diagnoses, therefore allowing them to successfully
find and manage the best therapeutical approach.
Alzheimer's Disease (AD), a chronic disorder
that slowly and progressively destroys neurons, was first described
by Alois Alzheimer in 1906. Even
though, the aetiology (the study of the cause) of AD is still
unknown, several possibilities such as extracellular β-amyloid and
hyperphosphorylated tau proteins hypothesises were investigated but
the results were not conclusive (Zekanowski et al., 2004).
However, new theories related to electrolytes like calcium,
magnesium, zinc and their relationships are being studied to find
how the neurodegenerative process gradually begins (Bojarski et
al., 2008).
The relationship between the dopaminergic and
cholinergic mechanisms was first studied in regards to postural
tremor in monkeys and circling movements in cats (Poirier et al.,
1974) in response to drugs. The measurement of specific enzymes
activities as well as the turnover rate of catecholamines and
indolamines, allow the understanding of the contribution of ChAT
(choline acetyl-transferase) and GAD synthesising enzyme to the
Krebs cycle (the metabolic pathway within the cells) in affecting
the release of ATP by the mitochondria, responsible for the level
of cellular energy that influence the internal and external
cellular homeostasis. In this respect, brain specific enzyme
activity of ChAT, tyrosine hydroxylase, tryptophan hydroxylase,
DOPA /5HTP decarboxylase and DBH and their biochemical parameters
were respectively studied in cats and rats using several drugs and
electrolytes such as aluminium, calcium, copper, iron etc (Bouchard
et al., 1981; Dontigny & Roberge, 1984; Nadeau & Roberge,
1988; Blais & Roberge, 1991; Fortin & Roberge, 1992;
Nucloseph et al., 1996).
To further understand the neurobiology of AD
through chemical events, memory mechanisms were studied in cats
using various learning tests such as "go-no-go discrimination,"
"delayed response," and "visual discrimination." In normal cats, an
increase in the specific ChAT activity corresponds to an increased
turnover rate of the neurotransmitters (Kitsikis et al.,
1973,1981., Boisvert, 1978; Everett & Roberge, 1981; Vachon et
al., 1983). On the other hand, the inducibility of ChAT
(choline acetyl-transferase) was studied in order to
understand how neuronutrition with appropriate nutrients will
favour the increased acetylcholine release. It was successfully
demonstrated by an increase in ChAT activity with nutrients such as
cobalamine, phosphatidylethanolamine and neutral amino acids.
Experiments and studies done on several species
demonstrated that the brain noradrenergic and cholinergic pathways
in the mesolimbic system are in a close relationship with the HPAS
Axis: cognitive disorders & depression taming emotions. In this
respect, early diagnosis at the age of 35, will allow to
distinguish between "senility", "senile dementia" related to age,
"vascular dementia" and the malignant disease called "AD"and will
later significantly contribute to clarify the real cause of
death. As AD is a multiparametrical and evolutive disease, an
appropriate follow-up could be developed based on a
neurobio-psycho-socio-environmental approach, to improve the
patient's quality of life.
In summary, the ChAT enzyme activity could be
induced and following several learning tests, an increase in
specific ChAT enzyme activity was observed as well as a significant
change in the turnover rate of serotonin and noradrenaline in the
structures belonging to the mesolimbic system. With this close
relationship with the HPAS Axis (cognitive disorders &
depression taming emotions, this clinical feature should be
clinically evaluated upon reaching 35 years of age (WHO, 2000).
Contact:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.